336 related articles for article (PubMed ID: 26743169)
1. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One?
Vaduganathan M; Bhatt DL
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):427-8. PubMed ID: 26912743
[No Abstract] [Full Text] [Related]
3. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
[TBL] [Abstract][Full Text] [Related]
4. GLS-409, an Antagonist of Both P2Y
Smolensky Koganov E; Michelson AD; Yanachkov IB; Yanachkova MI; Wright GE; Przyklenk K; Frelinger AL
Sci Rep; 2018 Sep; 8(1):14529. PubMed ID: 30266987
[TBL] [Abstract][Full Text] [Related]
5. SAR216471, an alternative to the use of currently available P2Y₁₂ receptor inhibitors?
Delesque-Touchard N; Pflieger AM; Bonnet-Lignon S; Millet L; Salel V; Boldron C; Lassalle G; Herbert JM; Savi P; Bono F
Thromb Res; 2014 Sep; 134(3):693-703. PubMed ID: 25064036
[TBL] [Abstract][Full Text] [Related]
6. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
[TBL] [Abstract][Full Text] [Related]
7. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL
Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
[TBL] [Abstract][Full Text] [Related]
9. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
[TBL] [Abstract][Full Text] [Related]
10. Can the PFA-100 be modified to detect P2Y12 inhibition?
Pidcock M; Harrison P
J Thromb Haemost; 2006 Jun; 4(6):1424-6. PubMed ID: 16706997
[No Abstract] [Full Text] [Related]
11. Pharmacodynamic interplay of the P2Y(1), P2Y(12), and TxA(2) pathways in platelets: the potential of triple antiplatelet therapy with P2Y(1) receptor antagonism.
Oestreich JH; Ferraris SP; Steinhubl SR; Akers WS
Thromb Res; 2013 Feb; 131(2):e64-70. PubMed ID: 23245937
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin.
Cattaneo M; Lecchi A
J Thromb Haemost; 2007 Mar; 5(3):577-82. PubMed ID: 17155953
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet activity, P2Y₁ and P2Y₁₂ inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'″-P¹ ,P⁴-dithio-P²,P³-chloromethylenetetraphosphate.
Chang H; Yanachkov IB; Dix EJ; Yanachkova M; Li Y; Barnard MR; Wright GE; Michelson AD; Frelinger AL
PLoS One; 2014; 9(4):e94780. PubMed ID: 24722456
[TBL] [Abstract][Full Text] [Related]
15. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
16. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity.
Storey RF; Sanderson HM; White AE; May JA; Cameron KE; Heptinstall S
Br J Haematol; 2000 Sep; 110(4):925-34. PubMed ID: 11054084
[TBL] [Abstract][Full Text] [Related]
17. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
18. Platelets Express Activated P2Y
Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
[TBL] [Abstract][Full Text] [Related]
19. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]